Staff

Staff

Prof. Dr. Dieter Deforce

Deforce Dieter

 

 

 

 

 

 

 

 

 

 

 

 

Prof. Dr. Dieter Deforce is the Director of the Laboratory of Pharmaceutical Biotechnology.

 

phone: ++32 9 264 80 67
fax: ++32 9 220 66 88
Dieter.Deforce@UGent.be

 

Van Nieuwerburgh Filip

Van Nieuwerburgh Filip

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

phone: ++32 9 264 80 48
fax: ++32 9 220 66 88

TITLE

Genomics and Proteomics

SUMMARY

Ongoing research:

      Second generation sequencing:

 

      • Member of the NXTGNT executive committee. NXTGNT is a service facility which makes 2 second generation sequencing technologies (Illumina GAIIx and Roche GS FLX) available for research projects.

  

      • Focus on second generation sequencing related bio-informatics with extensive experience in (hybrid) de novo assembly. The hybrid de novo assembly uses data from the 2 technologies to achieve a better and a cheaper assembly then when using data from only one of the technologies

  

    • Numerous next generation sequencing projects are ongoing in the field of forensics, medical genetics, pharmacogenetics, plant genetics, etc.

PUBLICATIONS

http://lib.ugent.be/bibliografie/801001335829

 

Decraene Sylvie

 

 

 

 

 

 

 

 

 

 

 

 

 

phone: ++32 9 264 80 62
fax: ++32 9 220 66 88

Dhaenens Maarten

Maarten Dhaenens

 

 

 

 

 

 

 

 

 

 

 

 

 

phone: ++32 9 264 83 56
fax: ++32 9 220 66 88

TITLE

 "A mass spectrometry journey through medical and molecular biology"

SUMMARY

Throughout the course of my PhD, the research focus has greatly shifted. The initial objective was reached when the discovered aberrant protein expression patterns in HLAB27 transgenic rat dendritic cells were confirmed with both videomicroscopy and flow cytometry: the dendritic cells from this animal model for Spondyloarthritis exert an endoplasmic reticulum stress due to HLAB27 misfolding, resulting in downregulated cytoskeletal dynamics. This latter deficiency results in lower motility and changed morphology, as well as a less efficient immunological synapse formation with T-cells. The overall downregulation of surface MHCII expression and increased apoptotic sensitivity of the tolerigenic CD4- dendritic cells are most probably also entwined with the deficient cytoskeleton.
An iTRAQ analysis on Chronic Lymphocytic Leukemia B-cells, which was initially set up to optimize the protocol of this new proteomics approach, led to the rediscovery of a histone clipping event that was first described over 35 years ago. In the light of current knowledge, this old proteolytical event could have far-reaching effects on hematopoiesis, through its interaction with the Polycomb Group of epigenetic modifiers. We have now unmasked this so-called “H2A-specific protease”. The obvious parallel between H2A clipping and the recently described histone H3 clipping in embryonic stem cells has inspired us to start the study of this model as well and to summarize all previous reports on histone clipping in a review.
More recently, we have set out to validate a new iTRAQ-based approach to identify and quantify posttranslational modifications. Validation of this approach for parallel expressional and posttranslational analysis is ongoing. Finally, the LabFBT proteomics platform has been used in collaboration with several different labs to tackle diverse biological and technical challenges such as the analysis of protein binders in historical paints, the search for mechanisms that can explain recrudescence of infection in pigs following stress, the pathogenicity of a mould that causes world-wide decline in amphibian populations, identification of di- and tripeptides with ACE inhibitory characteristics,…

PUBLICATIONS

http://lib.ugent.be/bibliografie/801002046454

 

Huyghe Inge

Gansemans Yannick

phone: ++32 9 264 81 38
fax: ++32 9 220 66 88